21.2 C
New York
Thursday, June 18, 2026

Tag: description

newssourceFORcompanyinformationcontent1marketreleases

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1...

Form 8.3 – Life Science REIT Plc

8.3

Form 8.5 (EPT/RI) – Apax Global Alpha Limited

FORM 8.5 (EPT/RI)

Jacobs to Support Critical Ireland Railway Infrastructure Program

Route modernization and expansion enabling greater regional accessibility Key regional and intercity corridor upgrade project commences DALLAS, July 22, 2025 /PRNewswire/ -- Jacobs (NYSE: J) has been...

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

New Found Gold Announces Preliminary Economic Assessment for the Queensway Gold Project

Solid low-cost production profile from year one via a phased mine plan:Phase 1: Low Initial capital cost of $155 million, builds average annual gold...

New Found Gold Announces Preliminary Economic Assessment for the Queensway Gold Project

Solid low-cost production profile from year one via a phased mine plan:Phase 1: Low Initial capital cost of $155 million, builds average annual gold...

Isdera Group Limited Announces Entering into a Merger Agreement with UY Scuti Acquisition Corp.

NEW YORK, July 21, 2025 /PRNewswire/ -- Isdera Group Limited, a Cayman Islands company ("Isdera Group" or the "Company"), a company that shall become...

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

Form 8.5 (EPT/RI) – Greencore Group Plc

FORM 8.5 (EPT/RI)

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

SOUTH SAN FRANCISCO, Calif., July 21, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDescription

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers